NCT05962021View on ClinicalTrials.gov

Neoadjuvant Toripalimab for Non-squamous NSCLC With EGFR Mutation

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

126

Participants

Timeline

Start Date

August 1, 2023

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Non Squamous Non Small Cell Lung CancerEGFR Positive Non-small Cell Lung Cancer
Interventions
DRUG

Toripalimab plus Chemotherapy

Therapy was administered on a 21-day regimen for 3 cycles, with Toripalimab (240mg, d1), carboplatin (AUC=5, d1) + pemetrexed (500 mg/m2, d1) for patients with lung adenocarcinoma and carboplatin (AUC=5, d1) + albumin-bound paclitaxel (260 mg/m2, d1) for patients with other subtypes.

All Listed Sponsors
collaborator

Shanghai Junshi Bioscience Co., Ltd.

OTHER

lead

Peking University People's Hospital

OTHER